SOLUBLE CD80 AS A THERAPEUTIC TO REVERSE IMMUNE SUPPRESSION IN CANCER PATIENTS

摘要

The present invention provides for a therapeutic cancer treatment using a soluble CD80 fusion protein that binds to PDL1 and inhibits PDL1-PD1 interactions thereby overcoming PDL1-induced immune suppression and restoring T cell activation.

主权项

1. A binding complex for binding to PD1 thereby activate tumor-specific T cells, the binding complex comprising a chimeric peptide and PDL1, wherein the chimeric peptide comprises a CD80 amino acid sequence, a modified sequence having 95% homology to the CD80 amino acid sequence or a fragment thereof and a Fc IgG1 amino acid sequence.